Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $23.8333.

Several research analysts have weighed in on ANRO shares. BTIG Research started coverage on Alto Neuroscience in a research report on Monday, November 17th. They issued a “buy” rating and a $27.00 price objective on the stock. HC Wainwright boosted their price target on shares of Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 24th. Wall Street Zen upgraded shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Jefferies Financial Group lifted their price objective on shares of Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th.

Alto Neuroscience Stock Down 7.2%

Alto Neuroscience stock opened at $18.44 on Friday. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $20.91. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The firm’s 50-day simple moving average is $14.20 and its 200 day simple moving average is $7.25. The stock has a market cap of $572.83 million, a PE ratio of -8.05 and a beta of 2.95.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. Research analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several hedge funds have recently made changes to their positions in ANRO. Bank of Montreal Can bought a new position in shares of Alto Neuroscience during the 2nd quarter worth $25,000. Ground Swell Capital LLC purchased a new stake in Alto Neuroscience during the second quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC bought a new position in Alto Neuroscience during the second quarter worth about $33,000. AlphaCore Capital LLC increased its stake in shares of Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Alto Neuroscience in the first quarter worth about $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.